Guidance Developed for Diagnosis, Management of Eosinophilic Esophagitis
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 24, 2025 -- In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are presented for the diagnosis and management of eosinophilic esophagitis (EoE).
Evan S. Dellon, M.D., M.P.H., from the University of North Carolina School of Medicine in Chapel Hill, and colleagues made recommendations across domains of diagnosis, treatment, monitoring, and assessment of response and pediatric-specific considerations for EoE.
The authors recommend that EoE is diagnosed based on the presence of symptoms of esophageal dysfunction and at least 15 eosinophils per high-power field on esophageal biopsy. A systematic endoscopic scoring system is recommended to characterize endoscopic findings of EoE at every endoscopy. To assess for histologic features consistent with EoE, at least six esophageal biopsies from at least two esophageal levels should be obtained. Eosinophil counts should be quantified on esophageal biopsies from every endoscopy performed. Proton pump inhibitors (PPIs) are suggested as a treatment for EoE, while swallowed topical steroids are recommended as a treatment. Use of either fluticasone propionate or budesonide is suggested for patients with EoE treated with topical steroids. An empiric food elimination diet is suggested for EoE treatment, but currently available allergy testing to direct food elimination diets is not suggested. Dupilumab is suggested for individuals aged 12 years or older and for pediatric patients who are nonresponsive to PPI therapy. Omalizumab is not suggested for EoE treatment. For esophageal strictures causing dysphagia, endoscopic dilation is suggested as an adjunct to medical therapy.
"For all treatments, cost and insurance coverage should be considered on an individual basis because there are scant cost-effectiveness data to currently support decisions," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...
Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...
Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.